Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Respiratory Tract Infection Treatment Market, by Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, and Others), by Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 35.64 Bn in 2017 and is projected to exhibit a CAGR of 6.5% over the forecast period (2018 – 2026).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2030
The respiratory tract infection treatment market is expected to exhibit exponential growth over the forecast period. This is owing to increasing pollution, which is resulting in rising number of cases of respiratory tract infection. According to a National Center for Biotechnology Information (NCBI), 2013, in the U.S., 25% people are suffering from upper respiratory tract infection due to pollution and it is the most common reason for patients to visit the doctors. Novel lung therapies are being developed by various research organizations for the treatment of critically ill patients with acute respiratory distress syndrome (ARDS). For instance, Draper Laboratory scientists are using unique manufacturing techniques and chip technology to precisely mimic blood vessels in the lungs, to treat patients with lung failure.
Furthermore, asthma is one among the major conditions that leads to respiratory diseases, which are characterized by recurring attacks of panting and wheezing. The severity and frequency of asthma differs from individual to individual. According to the Centers for Disease Control and Prevention (CDC), in 2015, 25 million people (1 in 13) in the U.S. were suffering from asthma. Furthermore, 6.2 million people below the age of 18 years suffered from asthma.
Browse 25 Market Data Tables and 22 Figures spread through 157 Pages and in-depth TOC on “Respiratory Tract Infection Treatment Market, by Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, and Others), by Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
To know the latest trends and insights related to respiratory tract infection treatment market Press Release, click the link below: https://bit.ly/3klAK4I
The respiratory tract infection treatment market growth is driven by factors such as strategies adopted by vendors for implementing new schemes and reimbursement rate for respiratory diseases that would attract the patients to undergo treatment. As per the data from GlaxoSmithKline (GSK) Australia, Trelegy Ellipta (single inhaler triple therapy for COPD) will be reimbursed by the Pharmaceutical Benefits Scheme (PBS) for suitable adults in Australia suffering from moderate to severe chronic obstructive pulmonary diseases (COPD) from June 1, 2018. Moreover, the market growth is expected to be driven by rising approval of new drugs by the Food and Drug Administration (FDA). For instance, in November 2017, the U.S. FDA approved Fasenra (Benralizumab) manufactured by AstraZeneca, a respiratory biologic for the patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Furthermore, in November 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the marketing authorization of Benralizumab. Benralizumab is also under regulatory review in Japan and several other countries.
Key Takeaways of the Respiratory Tract Infection Treatment Market:
- The global respiratory tract infection treatment market is expected to exhibit a CAGR of 6.5% during the forecast period (2018 – 2026). This is attributed to continuous technological advancements and rising incidence of respiratory diseases.
- Among drug class, non-steroidal anti-inflammatory drug (NSAIDS) segment is expected to exhibit rapid growth during the forecast period. This is due to easy availability of these drugs under over the counter (OTC) products at low price.
- However, antibiotics segment is expected to exhibit fastest growth rate in this market, as these drugs have improved pharmacokinetics that specifically target the respiratory tract infection and also due to rising prescription of antibiotics for curing respiratory tract infection
- Key players operating in the global respiratory tract infection treatment market include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2030
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
